{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:41:54Z","timestamp":1790854914531,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.ijpharm.2005.09.040","type":"journal-article","created":{"date-parts":[[2006,3,14]],"date-time":"2006-03-14T08:48:09Z","timestamp":1142326089000},"page":"120-126","source":"Crossref","is-referenced-by-count":75,"title":["Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases"],"prefix":"10.1016","volume":"314","author":[{"given":"N.","family":"Popovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Brundin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2005.09.040_bib1","unstructured":"Amgen Incorporated: Amgen's phase 2 study of GDNF for advanced Parkinson's disease fails to meet primary endpoint; six months of treatment showed biological effect but no clinical improvement, 2004. http:\/\/amgen.com\/news\/viewPR.jsp?id=585632."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0168-0102(00)00097-3","article-title":"The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages","volume":"36","author":"Aoi","year":"2000","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jconrel.2004.11.004","article-title":"Carbidopa\/levodopa-loaded biodegradable microspheres: in vivo evaluation on experimental Parkinsonism in rats","volume":"102","author":"Arica","year":"2005","journal-title":"J. Contr. Rel."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0168-3659(02)00353-X","article-title":"Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors","volume":"87","author":"Bensadoun","year":"2002","journal-title":"J. Contr. Rel."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0168-3659(99)00250-3","article-title":"Development of microspheres for neurological disorders: from basic to clinical applications","volume":"65","author":"Benoit","year":"2000","journal-title":"J. Contr. Rel."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib6","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1089\/hum.2004.15.968","article-title":"Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study","volume":"15","author":"Bloch","year":"2004","journal-title":"Hum. Gen. Ther."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib7","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1006\/nbdi.1997.0151","article-title":"Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease","volume":"4","author":"Bj\u00f6rklund","year":"1997","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/sct.1989.5.55","article-title":"Biocompatibility of a degradable controlled release polymer in the rabbit brain","volume":"5","author":"Brem","year":"1983","journal-title":"Sel. Cancer Ther."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib9","doi-asserted-by":"crossref","first-page":"5168","DOI":"10.1523\/JNEUROSCI.16-16-05168.1996","article-title":"Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease","volume":"16","author":"Emerich","year":"1996","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0963-6897(97)00035-3","article-title":"Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease","volume":"6","author":"Emerich","year":"1997","journal-title":"Cell Trans."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/386395a0","article-title":"Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease","volume":"386","author":"Emerich","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3727\/000000004783983404","article-title":"Dose-dependent neurochemical and functional protection afforded by encapsulated CNTF-producing cells","volume":"13","author":"Emerich","year":"2004","journal-title":"Cell Transpl."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0022-4804(64)80040-8","article-title":"The use of silicone rubber as a carrier for prolonged drug therapy","volume":"4","author":"Folkman","year":"1964","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib14","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.1016\/S0142-9612(03)00161-3","article-title":"Biocompatibility of implantable synthetic polymeric drug carriers: focus on brain biocompatibility","volume":"24","author":"Fournier","year":"2003","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/jps.10414","article-title":"A potential approach for decreasing the burst effect of protein from PLGA microspheres","volume":"92","author":"Fu","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nm850","article-title":"Direct brain infusion of glial cell line-derived nerotrophic factor in Parkinson disease","volume":"9","author":"Gill","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/syn.10063","article-title":"Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease","volume":"44","author":"Gouhier","year":"2002","journal-title":"Synapse"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0014-4886(90)90049-X","article-title":"NGF released from a polymer matrix prevents loss of ChAT expression in basal forebrain neurons following a fimbria-fornix lesion","volume":"110","author":"Hoffman","year":"1990","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3171\/jns.1989.71.1.0105","article-title":"Intracerebral drug delivery in rats with lesion-induced memory deficits","volume":"71","author":"Howard","year":"1989","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0142-9612(98)00019-2","article-title":"Poly(anhydride-co-imides): in vivo biocompatility in a rat model","volume":"19","author":"Ibim","year":"1998","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib21","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0142-9612(03)00601-X","article-title":"Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease","volume":"25","author":"Jollivet","year":"2004","journal-title":"Biomaterial"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.neulet.2003.11.051","article-title":"Long-term effect of intra-striatal glial cell line-derived neurotrophic factor-releasing microspheres in a partial rat model of Parkinson's disease","volume":"356","author":"Jollivet","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1046\/j.0953-816x.2001.01534.x","article-title":"Delayed infusion of GDNF promotes recovery of motor function I the partial lesion model of Parkinson's disease","volume":"13","author":"Kirik","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nn1175","article-title":"Localized striatal delivery of GDNF as a treatment for Parkinson disease","volume":"7","author":"Kirik","year":"2004","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0306-4522(95)00543-9","article-title":"Intrastriatal implants of polymer encapsulated cells genetically modified to secrete human nerve growth factor: trophic effects upon cholinergic and noncholinergic striatal neurons","volume":"72","author":"Kordower","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/0006-8993(95)00261-N","article-title":"Distribution of nerve growth factor following direct delivery to brain interstitium","volume":"680","author":"Krewson","year":"1995","journal-title":"Brain Res."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0006-8993(96)00378-2","article-title":"Transport and elimination of recombinant human NGF during long-term delivery to the brain","volume":"727","author":"Krewson","year":"1996","journal-title":"Brain Res."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1163\/156856296X00183","article-title":"Stabilization of nerve growth factor in controlled release polymers and in tissue","volume":"8","author":"Krewson","year":"1996","journal-title":"J. Biomater. Sci. Polym. Ed."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/jbm.820200106","article-title":"Bioerodible polyanhydrides as drug-carrier matrices. II. Biocompatibility and chemical reactivity","volume":"20","author":"Leong","year":"1986","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0963-6897(97)00169-3","article-title":"Therapeutic potential of a polymer-encapsulated l-DOPA and dopamine-producing cell in rodent and primate models of Parkinson's disease","volume":"7","author":"Lindner","year":"1998","journal-title":"Cell Trans."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib31","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1073\/pnas.96.8.4536","article-title":"Millimeter-scale positioning of a nerve growth factor source and biological activity in the brain","volume":"96","author":"Mahoney","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib32","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1523\/JNEUROSCI.15-08-05668.1995","article-title":"CNS-derived neural progenitor cells for gene transfer of nerve growth factor to the adult rat brain: complete rescue of axotomized cholinergic neurons after transplantation into the septum","volume":"15","author":"Martinez-Serrano","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0197-0186(94)90049-3","article-title":"Transmitter-loaded polymeric microspheres induce regrowth of dopaminergic nerve terminals in striata of rats with 6-OHDA induced parkinsonism","volume":"25","author":"McRae","year":"1994","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF02816119","article-title":"Catecholamine-containing biodegradable microspheres implants as a novel approach in the treatment of CNS neurodegenerative disease. A review of experimental studies in DA-lesioned rats","volume":"9","author":"McRae","year":"1994","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1999.7253","article-title":"Intracerebral implantation of NGF-releasing biodegradable microspheres protects striatum against excitotoxic damage","volume":"161","author":"Menei","year":"2000","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0304-3940(94)90186-4","article-title":"Is there a long-lasting effect of a short-term nerve growth factor application on axotomized rat septohippocammpal neurons?","volume":"173","author":"Naumann","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib37","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0304-3940(01)02534-4","article-title":"The fate of biodegradable microspheres injected into rat brain","volume":"323","author":"Nicholas","year":"2002","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib38","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.20374","article-title":"Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study","volume":"57","author":"Patel","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib39","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0142-9612(00)00141-1","article-title":"Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons","volume":"21","author":"P\u00e9an","year":"2000","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib40","unstructured":"Pollack, A. 2005. Patients in test won\u2019t get drug, Amgen decides. NY Times, February 12, C1, C2."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0142-9612(83)90054-6","article-title":"Bioerodible polyanhydrides for controlled drug delivery","volume":"4","author":"Rosen","year":"1983","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10717549709051884","article-title":"Adsorption of brain proteins on the surface of poly (d,l-lactide-co-glycolide) (PLGA) microspheres","volume":"4","author":"Saini","year":"1997","journal-title":"Drug Del."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1023\/A:1018824324275","article-title":"Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems","volume":"16","author":"Saltzman","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib44","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0963-6897(94)00047-N","article-title":"Polymer-encapsulated schwannoma cells expressing human nerve growth factor promote the survival of cholinergic neurons after a fimbria-fornix transection","volume":"4","author":"Schinstine","year":"1995","journal-title":"Cell Trans."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib45","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3171\/jns.2005.102.2.0216","article-title":"Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor","volume":"102","author":"Slevin","year":"2005","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib46","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0142-9612(89)90063-X","article-title":"In vitro and in vivo degradation of poly(d,l-lactide:glycolide) type microspheres made by solvent evaporation method","volume":"10","author":"Spenlehauer","year":"1989","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib47","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jbm.820230209","article-title":"Brain biocompatibility of a biodegradable controlled release polymer in rats","volume":"23","author":"Tamargo","year":"1989","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1523\/JNEUROSCI.17-01-00325.1997","article-title":"GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine","volume":"17","author":"Tseng","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.410300502","article-title":"Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain","volume":"30","author":"Tuszynski","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib50","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0306-4522(94)90229-1","article-title":"Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA","volume":"61","author":"Venero","year":"1994","journal-title":"Neuroscience"},{"key":"10.1016\/j.ijpharm.2005.09.040_bib51","doi-asserted-by":"crossref","first-page":"9231","DOI":"10.1073\/pnas.83.23.9231","article-title":"Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection","volume":"83","author":"Williams","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/exnr.1996.0123","article-title":"Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: behavioral and anatomical consequences","volume":"140","author":"Winn","year":"1996","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ijpharm.2005.09.040_bib53","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0165-0173(01)00098-4","article-title":"Sustained delivery of GDNF: towards a treatment for Parkinson's disease","volume":"36","author":"Zurn","year":"2001","journal-title":"Brain Res. Rev."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306000925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517306000925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T05:12:42Z","timestamp":1555477962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517306000925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0378517306000925"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2005.09.040","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}